FDA Type B Meeting on Potential Accelerated Approval Pathway for Givastomig in Gastric Cancer Concluded March 24, 2026
Imfinzi approved in the EU in patients with early gastric and gastroesophageal cancers March 17, 2026
First Patient Dosed in Ph 2 Study of Givastomig-Nivolumab combo in Patients with 1L Metastatic HER2-neg Gastric Cancer February 25, 2026
First Patient Dosed in Ph 1a/2a Trial of DPTX3186 in Advanced Solid Tumors, Focused on Gastric Cancer February 9, 2026
Results announced from Ph 3 study of Anbenitamab (KN026) in HER2+ve gastric or gastroesophageal junction cancer (GC/GEJ) February 1, 2026
Imfinzi perioperative regimen recommended for approval in the EU by CHMP for patients with early gastric and gastroesophageal cancers February 1, 2026
Ph 1/2a Data of IMC002 Highlighted a Durable Complete Response Beyond 1 Year and a 66.7% ORR in Advanced GC/GEJ January 18, 2026
VYLOY™ (zolbetuximab) + Chemo Associated with Enhanced Survival Outcomes when Common Adverse Events are Effectively Managed, According to New Ad Hoc Analyses January 11, 2026
Ziihera (zanidatamab-hrii) Results in 1L HER2+ Locally Advanced or Metastatic GEA Announced Including 2+ Years Median OS Benefit January 11, 2026
NDA for savolitinib for locally advanced/metastatic GC/GEJ adenocarcinoma patients with MET amplification accepted and granted priority review by the China NMPA December 30, 2025
Cadonilimab Receives FDA Clearance for Global Ph 3 1L Gastric Cancer Trial vs. Nivolumab December 15, 2025
Imfinzi approved in the US as perioperative immunotherapy for patients with early gastric/GEJ cancers December 2, 2025
Ph 3 Trial of HANSIZHUANG + Chemo Meets Primary Endpoint in Neoadjuvant/ Adjuvant Gastric Cancer, Greenlighting Early NDA Submission October 16, 2025
ONO-4578, Opdivo and Chemo combo Met the Primary Endpoint in Ph 2 Trial in Patients with 1L HER2-neg recurrent Gastric Cancer October 15, 2025
Initial clinical data for BDC-4182 Ph 1 dose escalation study now expected in 3Q 2026 October 7, 2025
Dewpoint Therapeutics Closes Series D Financing to Advance First-in-Class Condensate Modulator (c-mod) into Clinical Development for Gastric Cancer September 16, 2025
NMPA accepts NDA for KN026 in patients with HER2+ve locally advanced, recurrent, or metastatic gastric or GEJ cancer September 16, 2025
